FDA has approved Zealand Pharma's Investigative New Drug application (IND) for ZP1848 to be administered in humans
ZP1848 is developed for the prevention and treatment of Crohn's Disease.
05-Feb-2009 -
Zealand Pharma advances ZP1848, a Glucagon-Like Peptide-2 (GLP-2) agonist, into Phase I clinical trials. ZP1848, a peptide which incorporates Zealand's proprietary SIP® technology is developed as a therapy for the prevention and treatment of Crohn's Disease.
The Phase I study is a double-blind, ...
absorption
clinical trials
colitis ulcerosa
+8